Research articlePublished 15 Jan 2025

A Systematic Biology Advances on sgRNA Design to Develop an Immunogenic Drug against Cancer Using CRISPR

Authors: Disha Patel, Khushal Patel

Journal of Cancer Research and Immuno-Oncology

Volume 11 · Issue 1 · Pages 1–6

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

In the field of genome editing, CRISPR/Cas9 is more suitable for clinical therapeutic applications, especially in the treatment of cancer. Here we wanted to design sgRNA that targets specific genes of helper T cells and cytotoxic T cells to alter them so that they can attack tumor cells. In other words, activating the immune system to treat cancer through the development of an immunogenic living drug. Among the main methods, the sgRNA of the target genes (PDCD-1, CTLA-4 and NYESO-1) was designed using the bioinformatics tool Benchling. The designed sgRNA was then cloned in silico into a lentivirus-based vector using the SnapGene gene designer. Isolation of an immunogenic drug can be done by transferring designed clones in vitro into the host and isolating pseudo-HIV viruses from the host, which consists of designed sgRNAs along with the CRISPR/Cas-9 machinery as a genome surrounded by an HIV viral envelope capable of binding T helper cells and cytotoxic T cells detected by protein-protein docking with PatchDock, followed by significantly improved results by FireDock and visualization in BIOVIA discovery studio. The sgRNAs were successfully engineered with good efficiency and potency to knock out PDCD-1 and CTLA-4 along with knock-in of NYESO-1. The developed immunogenic live drug has also shown positive results in binding efficiency to both T helper cells and cytotoxic T cells. Overall, this study showed that the key in silico results can be helpful in the development of immunogenic live drugs and will serve as a future aspect for in vitro treatment of cancer.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Longdom does not store it.

Try:

More from this journal

The newest in Journal of Cancer Research and Immuno-Oncology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Cancer Research and Immuno-Oncology
  • SubjectOncology & Cancer
  • SubjectImmunology & Microbiology
  • BylineArticles whose byline prints “Disha Patel”
  • BylineArticles whose byline prints “Khushal Patel”